Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-12-15
2000-01-25
Dentz, Bernard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5142305, 514300, 514333, 544105, 544335, 546 81, 546 82, 546122, 546256, 546115, 546118, 5483061, A61K 31435, C07D47104
Patent
active
060179260
ABSTRACT:
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.
REFERENCES:
patent: 5455243 (1995-10-01), Duggan et al.
patent: 5668159 (1997-09-01), Jin et al.
Askew Ben C.
Coleman Paul J.
Duggan Mark E.
Halczenko Wasyl
Hutchinson John H.
Dentz Bernard
Durette Philippe L.
Merck & Co. , Inc.
Sabatelli Anthony D.
Winokur Melvin
LandOfFree
Integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2316148